American Urological Association

Research Presented at AUA 2024 Indicates the Cost of Prescription Drugs Is A Significant Barrier To Care

Retrieved on: 
Sonntag, Mai 5, 2024
Urology, Interview, Woman, American Urological Association, Abstract (summary), Abstract, Insurance, Plasma protein binding, Research, Patient, Communication, Annual general meeting, SAN

Researchers will present their study findings covering important updates on the cost of care in San Antonio, Texas, from May 3 to 6.

Key Points: 
  • Researchers will present their study findings covering important updates on the cost of care in San Antonio, Texas, from May 3 to 6.
  • Ruchika Talwar, MD, urologist and clinical instructor in the Vanderbilt University School of Medicine’s Department of Urology, moderated a virtual press session with the abstract authors, providing key insights into their research.
  • “The more we highlight and disseminate these findings, the more we can make both urologists and patients aware of the resources that exist to help mitigate the financial burden of prescription drugs,” said Dr. Talwar.
  • To arrange an interview with an expert, please contact the AUA Communications Team at [email protected].

Results from Pivotal Clinical Study Demonstrate Potential of Nucleix’s Bladder EpiCheck® to Improve Disease Recurrence Detection in Non-Muscle Invasive Bladder Cancer (NMIBC) Surveillance

Retrieved on: 
Montag, Mai 6, 2024
Biotechnology, FDA, Health, General Health, Oncology, Health Technology, Other Science, Medical Devices, Research, Science, Clinical Trials, Western University, Cystoscopy, Risk, Food, Urinary bladder, American Urological Association, Recurrence, Trial of the century, PCR, Patient, AUA, MBA, Neoplasm, Clinical trial, Annual general meeting, Bladder cancer, Liquid biopsy, Medical imaging

The data presented demonstrated Bladder EpiCheck’s potential to improve timely disease recurrence detection and compliance with NMIBC surveillance.

Key Points: 
  • The data presented demonstrated Bladder EpiCheck’s potential to improve timely disease recurrence detection and compliance with NMIBC surveillance.
  • “The results from our pivotal clinical study not only underscore the potential of Bladder EpiCheck as a non-invasive method for tumor recurrence detection in patients previously diagnosed with NMIBC but also signal a transformative shift in NMIBC surveillance,” said Aharona Shuali, MD, MBA, Vice President of Medical Affairs at Nucleix.
  • “The performance of Bladder EpiCheck in this clinical trial demonstrates its potential to be used as a non-invasive test for detecting bladder cancer recurrence.
  • Ongoing research will determine if Bladder EpiCheck can be used to replace some cystoscopies and thereby reduce the burden of bladder cancer surveillance for patients and health systems alike.”
    During the AUA Annual Meeting on May 5, 2024, these results were presented by Dr. Inman in a podium presentation titled “Pivotal Study Evaluating Performance of Bladder EpiCheck, an FDA cleared test, in Non-Muscle Invasive Bladder Cancer.”

14 Studies Presented at AUA 2024 Show Decipher Tests’ Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease Understanding

Retrieved on: 
Montag, Mai 6, 2024
Oncology, Health, Technology, Health Technology, Genetics, Artificial Intelligence, Biotechnology, RUO, University, Prostate, NCCN, RC, International, RP, Risk, Grade, American Urological Association, Survival, Neoadjuvant therapy, PSA, Columbia University, Integration, Research, Pathology, GSC, Prostate cancer, Prostate-specific antigen, University of Michigan, Patient, NOC, Urology, Intelligence, AUA, MRI, Biopsy, Gene expression, Diagnosis, MUSIC, Waiting, Bladder cancer, Radical, Medical imaging

(Nasdaq: VCYT), a leading cancer diagnostics company, today announced that data from 14 presentations at AUA 2024, the annual meeting of the American Urological Association, show that the Decipher Prostate and Decipher Bladder Genomic Classifiers provide better prognostic information for patients with prostate and bladder cancer, compared to standard approaches.

Key Points: 
  • (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that data from 14 presentations at AUA 2024, the annual meeting of the American Urological Association, show that the Decipher Prostate and Decipher Bladder Genomic Classifiers provide better prognostic information for patients with prostate and bladder cancer, compared to standard approaches.
  • They also show that the research-use-only Decipher GRID (Genomic Resource for Intelligent Discovery) tool is helping to advance scientific understanding of these diseases.
  • Summary: The Decipher Prostate Genomic Classifier is associated with adverse pathology in patients eligible for Active Surveillance (AS) who were treated with radical prostatectomy (RP).
  • Podium Presentation PD42-03 : Understanding Population-Wide Genomic Risk Distribution and Integrating Clinical-Genomic Risk for Prognostication in Prostate Cancer.

Favorable Clinical Data for Applaud Medical’s Novel Technology for Treating Urinary Stones Presented During the 2024 AUA Annual Meeting

Retrieved on: 
Montag, Mai 6, 2024
Biotechnology, Health, Clinical Trials, Other Health, Pain, ELS, Kidney, Safety, American Urological Association, System, MD, BRIO, Fluoroscopy, Patient, Medicine, AUA, Ureter, Trial of the century, Assistant, Standard of care, Annual general meeting, Microbubble, Lithotripsy, Medical imaging

Applaud Medical, an emerging leader in the treatment of urinary stones, today announced positive results from a prospective, multicenter study of the company’s BRIO Enhanced Lithotripsy System (ELS) for the treatment of obstructive ureteral stones.

Key Points: 
  • Applaud Medical, an emerging leader in the treatment of urinary stones, today announced positive results from a prospective, multicenter study of the company’s BRIO Enhanced Lithotripsy System (ELS) for the treatment of obstructive ureteral stones.
  • The results were presented as a podium presentation during the American Urological Association's (AUA) 2024 Annual Meeting held in San Antonio, Texas.
  • The study combined Applaud Medical’s proprietary acoustically enhanced microbubbles with a low-pressure ultrasound system to treat ureteral stones.
  • Our solution aims to eliminate ureteral stones quickly, affordably, and without general anesthesia or fluoroscopy, bringing it to a physician’s office and other non-hospital settings.”

Final Five-Year Analysis of Phase 3 Data With ADSTILADRIN® (nadofaragene firadenovec-vncg) Shows Durable Bladder Preservation and Consistent Long-Term Safety in BCG-unresponsive NMIBC

Retrieved on: 
Montag, Mai 6, 2024
Oncology, Health, Managed Care, Clinical Trials, Pharmaceutical, Biotechnology, FDA, Safety, Food, American Urological Association, Survival rate, Grady Memorial Hospital, Month, Recurrence, Carcinoma in situ, Nadofaragene firadenovec, BCG, Disease, CIS, Patient, Ferring Pharmaceuticals, NMIBC, AUA, Assistant, Annual general meeting, Journal, Pharmaceutical industry

Ferring Pharmaceuticals today announced the final 60-month follow-up data from the Phase 3 study of ADSTILADRIN® (nadofaragene firadenovec-vncg) were presented at the American Urological Association (AUA) 2024 Annual Meeting.

Key Points: 
  • Ferring Pharmaceuticals today announced the final 60-month follow-up data from the Phase 3 study of ADSTILADRIN® (nadofaragene firadenovec-vncg) were presented at the American Urological Association (AUA) 2024 Annual Meeting.
  • These data, which are the longest follow-up of efficacy and safety data reported for a novel agent for BCG-unresponsive NMIBC, were simultaneously published ahead of print and will be included in the July issue of The Journal of Urology®.
  • ADSTILADRIN is the first and only intravesical non-replicating adenoviral vector-based gene therapy approved by the U.S. Food and Drug Administration (FDA) in patients with high-risk BCG-unresponsive NMIBC with CIS with or without papillary tumors.
  • The mechanism of action of ADSTILADRIN is designed to deliver the human interferon-alfa 2b gene (IFNα2b) directly into the bladder to enable secretion of interferon alfa-2b protein with a single treatment every three months.

New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy

Retrieved on: 
Sonntag, Mai 5, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Hope, Hospital, UTUC, American Urological Association, RFS, Recurrence, MD, IQR, Disease, Patient, Clutch (eggs), Mitomycins, Neoplasm, Massachusetts General Hospital, Central Sindical Angolana, Medical imaging

Among the 30% of the complete responders who received maintenance therapy, RFS at 24 months was 100%, vs. 61% for those who did not receive maintenance therapy.

Key Points: 
  • Among the 30% of the complete responders who received maintenance therapy, RFS at 24 months was 100%, vs. 61% for those who did not receive maintenance therapy.
  • “Notably, there seems to be no discernible difference in disease recurrence based on tumor characteristics or timing of administration, including primary chemoablation or post-endoscopic ablation.
  • Data was collected from 15 centers on patients treated with JELMYTO for upper tract urothelial cancers (UTUC).
  • Recurrence-free survival was calculated in 53 patients with LGTa disease at baseline who had no evidence of disease following JELMYTO induction.

New Study Demonstrates Avenda Health's Unfold AI to Better Predict Focal Therapy Success by 77% Percent as Compared to Standard Methods

Retrieved on: 
Mittwoch, Mai 8, 2024
UCLA, FDA, ECS, AI, American Urological Association, Health, Unfold, MD, PSA, Doctor of Philosophy, Prostate cancer, GG5, Patient, GG1, Physician, AUA, MRI, Biopsy, UCLA Health, Neoplasm, GG, Quality of life, Cryotherapy, Medical imaging

CULVER CITY, Calif., May 8, 2024 /PRNewswire/ -- Avenda Health, an AI healthcare company creating the future of personalized prostate cancer care, unveils the results of a new UCLA study examining the role of AI in identifying tumor margins and predicting the efficacy of focal therapy treatments. The study titled "Software to Determine Extent of Tumor Margins in Focal Therapy," was presented at the 2024 American Urological Association's (AUA) annual meeting by Wayne Brisbane, MD, assistant professor at UCLA Health. It demonstrated that Unfold AI, Avenda Health's AI-powered cancer mapping technology, was a better predictor of focal therapy success than other factors, including the size or grade of the tumor.

Key Points: 
  • It demonstrated that Unfold AI , Avenda Health's AI-powered cancer mapping technology, was a better predictor of focal therapy success than other factors, including the size or grade of the tumor.
  • In the study, FDA-cleared Unfold AI technology was retrospectively applied to 118 previously untreated men undergoing hemi-gland cryotherapy for prostate cancer ablation.
  • MRI-guided biopsies, both targeted and systematic, were performed before cryotherapy and six months after cryotherapy to assess treatment outcomes.
  • "This more comprehensive approach enhances our ability to predict treatment outcomes and tailor interventions effectively to individual patient needs."

Sumitomo Pharma Presents Urology and Oncology Data at AUA 2024 Annual Meeting

Retrieved on: 
Dienstag, Mai 7, 2024
American Urological Association, SMPA, Week, The Journal of Urology, Urination, Vibegron, Overactive bladder, Safety, BPH, AUA, OAB, Pharmaceutical industry

MARLBOROUGH, Mass., May 7, 2024 /PRNewswire/ -- Sumitomo Pharma America, Inc., (SMPA) today announced the presentation of data from URO-901-3005, a Phase 3 randomized, double-blind, parallel-group, fixed-dose study evaluating the efficacy, safety, and tolerability of vibegron (GEMTESA®) versus placebo over 24 weeks in men living with overactive bladder (OAB) and receiving pharmacological therapy for benign prostatic hyperplasia (BPH) at the American Urological Association (AUA) Annual Meeting. Following the podium presentation at AUA, these results were published in Journal of Urology.

Key Points: 
  • Following the podium presentation at AUA, these results were published in Journal of Urology .
  • "There is currently no approved treatment for persistent OAB symptoms in men who are receiving treatment for BPH.
  • We are happy to share these results with the scientific community at AUA."
  • "We are proud to have our urology and oncology teams together and among the leaders at AUA sharing positive data that underpins our steadfast commitment to those living with unmet urological conditions."

TAR-210 results show 90% recurrence-free survival and 90% complete response in patients with high-risk and intermediate-risk non-muscle-invasive bladder cancer, respectively

Retrieved on: 
Sonntag, Mai 5, 2024
UTI, Congress, FDA, FGFR, Cancer, Urinary diversion, Pyelonephritis, Erdafitinib, Hospital, Safety, Food, American Urological Association, Survival rate, FGFR3, Johnson & Johnson, Recurrence, Abstract, Cohort, BCG, PD-1, PD-L1, Disease, Bladder cancer, Patient, Medicine, AUA, Urinary bladder, MUC, Face, SAN, Sepsis, EAU, Pharmaceutical industry

SAN ANTONIO, May 5, 2024 /PRNewswire/ -- Johnson & Johnson announced today updated results from an open-label, multicenter, multi-cohort Phase 1 study of the safety and efficacy of TAR-210, an intravesical targeted releasing system designed to provide sustained, local release of erdafitinib into the bladder, in patients with non–muscle-invasive bladder cancer (NMIBC) with select FGFR alterations. These data were featured today in an Oral Presentation Session (Abstract # PD48-02) at the 2024 American Urological Association (AUA) Annual Meeting taking place May 3-6, 2024, in San Antonio, Texas.

Key Points: 
  • First results were featured at the European Society for Medical Oncology 2023 Congress, with interim results presented at the European Association of Urology (EAU) 2024 Annual Congress.
  • "Results presented today further underscore that TAR-210 for the localized treatment of bladder cancer may offer a promising alternative for patients with limited treatment options."
  • At the data cutoff of March 22, 2024, 64 patients had been treated with TAR-210 across the 2 cohorts.
  • Of the 21 patients in C1 with HR-NMIBC, the 12-month recurrence-free (RF) survival rate was 90%.

Research Demonstrates How Technology and AI Can Improve Urologic Health

Retrieved on: 
Sonntag, Mai 5, 2024
American Urological Association, Abstract (summary), Health, Abstract, Urology, Annual general meeting, MD, Patient, Research, Algorithm, SAN, Medical device

Researchers will present their study findings covering important updates on technology in San Antonio, Texas, from May 3 to 6.

Key Points: 
  • Researchers will present their study findings covering important updates on technology in San Antonio, Texas, from May 3 to 6.
  • Jacob Taylor, MD, urologic oncology fellow at UT Southwestern Medical Center, moderated a virtual press session with the abstract authors, providing key insights into their research.
  • “This is all very exciting data and new technology that is already here and being used with patients,” said Dr. Taylor.
  • “I think these studies will improve patient care for a wide range of the most common urologic conditions.”
    The following abstracts are covered in the moderated panel: